Literature DB >> 20714240

Human responses to pulmonary arterial hypertension: review of the literature.

Lea Ann Matura1, Diane L Carroll.   

Abstract

Pulmonary arterial hypertension (PAH) is a devastating disease characterized by elevation in pulmonary artery pressures causing progressive symptoms that lead to functional decline and poor quality of life. There are multiple causes of PAH including familial disease, connective tissue disease, and HIV. The estimated life expectancy is 4 years after onset of symptoms and approximately 6 to 7 years with PAH treatment. Much of the current research has focused on pharmacological treatments to improve functional status and decrease mortality. A comprehensive literature review was conducted using the CINAHL, PubMed, and MEDLINE to identify and synthesize current studies on human responses to PAH organized by emotional responses and physical functioning. Eight studies fulfilled the search criteria. Patients with PAH were learning to cope and live with uncertainty and treatment. Pulmonary arterial hypertension produced the emotional responses of anxiety, depression, and panic attacks along with impairments in cognition and memory as well as reductions in physical functioning.

Entities:  

Mesh:

Year:  2010        PMID: 20714240     DOI: 10.1097/JCN.0b013e3181d25458

Source DB:  PubMed          Journal:  J Cardiovasc Nurs        ISSN: 0889-4655            Impact factor:   2.083


  6 in total

1.  Physician attitudes toward palliative care for patients with pulmonary arterial hypertension: results of a cross-sectional survey.

Authors:  Eric R Fenstad; Tait D Shanafelt; Jeff A Sloan; Paul J Novotny; Louise A Durst; Robert P Frantz; Michael D McGoon; Keith M Swetz
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

Review 2.  Systematic Review of the Economic Burden of Pulmonary Arterial Hypertension.

Authors:  Shuyan Gu; Huimei Hu; Hengjin Dong
Journal:  Pharmacoeconomics       Date:  2016-06       Impact factor: 4.981

Review 3.  Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension.

Authors:  Shuyan Gu; Huimei Hu; Hengjin Dong
Journal:  Pharmacoeconomics       Date:  2016-08       Impact factor: 4.981

4.  Immunoglobulin G anti-endothelial cell antibodies: inducers of endothelial cell apoptosis in pulmonary arterial hypertension?

Authors:  S J Arends; J G M C Damoiseaux; A M Duijvestijn; L Debrus-Palmans; M Vroomen; K A Boomars; H-P Brunner-La Rocca; C P M Reutelingsperger; J W Cohen Tervaert; P van Paassen
Journal:  Clin Exp Immunol       Date:  2013-12       Impact factor: 4.330

5.  The trajectory to diagnosis with pulmonary arterial hypertension: a qualitative study.

Authors:  Ian Armstrong; Nikki Rochnia; Carl Harries; Sarah Bundock; Janelle Yorke
Journal:  BMJ Open       Date:  2012-04-18       Impact factor: 2.692

6.  A pilot randomised controlled trial investigating a mindfulness-based stress reduction (MBSR) intervention in individuals with pulmonary arterial hypertension (PAH): the PATHWAYS study.

Authors:  R M R Tulloh; V Garratt; J Tagney; J Turner-Cobb; E Marques; R Greenwood; L Howard; W Gin-Sing; A Barton; P Ewings; P Craggs; W Hollingworth
Journal:  Pilot Feasibility Stud       Date:  2018-05-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.